Showing results (61-70 of 702) with videos related to

Sort By:
Pageof 71
Alzheimer Disease and Associated Disorders|February 24, 2001
Haloperidol disrupts, clozapine reinstates the circadian rest-activity cycle in a patient with early-onset Alzheimer diseaseA Wirz-Justice, E Werth, E Savaskan, et al.
Psychopharmacology|January 1, 1984
Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesiaF Müller-Spahn, M Ackenheil, M Albus, et al.
Neuroscience|August 5, 2003
Beta-amyloid modulates tyrosine kinase B receptor expression in SHSY5Y neuroblastoma cells: influence of the antioxidant melatoninG Olivieri, U Otten, F Meier, et al.
Journal of Neurochemistry|January 9, 2001
N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on beta-amyloid secretion and tau phosphorylationG Olivieri, G Baysang, F Meier, et al.
Neurology & Clinical Neurophysiology : NCN|May 25, 2002
Oxidative stress modulates tyrosine kinase receptor A and p75 receptor (low-affinity nerve growth factor receptor) expression in SHSY5Y neuroblastoma cellsG Olivieri, U Otten, F Meier, et al.
Neuroscience Letters|July 11, 2001
Cerebrovascular melatonin MT1-receptor alterations in patients with Alzheimer's diseaseE Savaskan, G Olivieri, L Brydon, et al.
Der Nervenarzt|May 5, 1998
[The social status of schizophrenic patients]P Müller, W Gaebel, B Bandelow, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|April 25, 2003
Is interval medication a successful treatment regimen for schizophrenic patients with critical attitudes towards treatment?F Godemann, M Linden, W Gaebel, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 1, 1992
Depressive syndromes in schizophrenic patients under neuroleptic therapy. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich, Federal Republic of GermanyB Bandelow, P Müller, U Frick, et al.
Schizophrenia Bulletin|February 5, 2002
A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 yearsM Linden, F Godemann, W Gaebel, et al.
Pageof 71